BELLICUM PHARMACEUTICALS, INC Uncategorized Contracts & Agreements
15 Contracts & Agreements
- Description of (Filed With SEC on March 31, 2023)
- Cancer Research Grant Contract, dated July 27, 2011, by and between the Registrant and the Cancer Prevention and Research Institute of Texas (Filed With SEC on November 5, 2020)
- Omnibus Amendment Agreement, dated October 3, 2014, by and between Registrant and ARIAD Pharmaceuticals, Inc (Filed With SEC on November 5, 2020)
- Description of Securities (Filed With SEC on March 12, 2020)
- Open Market Sale AgreementSM, dated October 5, 2018, by and between Bellicum Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on October 5, 2018)
- Cancer Research Grant Contract with the Cancer Prevention and Research Institute of Texas, dated August 9, 2017 (Filed With SEC on November 7, 2017)
- Letter agreement by and between the registrant and Alan A. Musso, effective August 3, 2017 (Filed With SEC on November 7, 2017)
- CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT BETWEEN ADAPTIMMUNE LIMITED AND BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on March 13, 2017)
- BELLICUM PHARMACEUTICALS, INC. SPONSORED RESEARCH AGREEMENT NO. 2 (Filed With SEC on August 8, 2016)
- Additional abbreviations may also be used though not in the above list. (Filed With SEC on December 9, 2014)
- EXCLUSIVELICENSE AGREEMENT Re: BCM BLG # 13-040 Entitled Methods for Inducing Selective Apoptosis (Filed With SEC on November 18, 2014)
- EXCLUSIVELICENSE AGREEMENT BAYLOR COLLEGE OF MEDICINE BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on November 18, 2014)
- EXCLUSIVELICENSE AGREEMENT BAYLOR COLLEGE OF MEDICINE BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on November 18, 2014)
- OMNIBUSAMENDMENT AGREEMENT (Filed With SEC on November 18, 2014)
- NOTICE OF EXPANSION OF LICENSED FIELD TO OBTAIN ADDITIONAL EXCLUSIVE RIGHTS (Filed With SEC on November 18, 2014)
